Marinomed Biotech AG: Launch of new moisturizing Carragelose eye drops in Austria
Marinomed Biotech AG (VSE:MARI) announces that the Austrian distribution partner Sigmapharm has launched the moisturizing eye drops under the trade name “Coldamaris protect” further to a license deal signed in 2023. The eye drops complement the existing Carragelose over-the-counter (OTC) product portfolio consisting of nasal sprays and throat products for the prophylaxis and treatment of viral respiratory diseases. In a clinical study conducted in Spain in 2024, the eye drops improved dry-eye related symptoms by remarkable 54% while being well tolerated by patients with mild to moderate dry eye syndrome.
In 2024, the Carragelose business has been sold to the French Company Unither Pharmaceuticals. Marinomed now supports Unither in transferring the business and successfully continuing the growth of the portfolio. The launch of the eye drops is an important milestone for reaching contractually agreed milestones regarding the earn-out components of the contract.
Furthermore, Marinomed has made considerable progress in transferring the Carragelose product portfolio to the new medical device regulation (MDR). Next to other Carragelose nasal sprays, now also the decongestant nasal spray, containing a combination of Carragelose and sorbitol, has received the declaration of conformity und the MDR. The MDR, which replaces the previously valid medical device directive (MDD), sets new EU-wide standards regarding the requirements for safety, performance, quality of clinical data and overall technical documentation for medical devices.
Eva Prieschl-Grassauer, CSO of Marinomed, comments: “Together with an outstanding safety profile and other key benefits, Carragelose is an ideal compound for providing relief for dry eyes. Introducing the Carragelose eye drops to the product range is a logical addition and complements the existing product portfolio. This launch as well as the ongoing 2 transfer of the products to the new MDR supports the positive development of the Carragelose portfolio, which also influences the earn-out components of the deal between Unither and Marinomed.”
Contact
PR: Lucia Ziegler
Marinomed Biotech AG
T: +43 2262 90300 158
E-Mail: pr@marinomed.com